Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4

Conditions

Sarcoma, Kaposi 4Neoplasms 4HIV Infections 4Acquired Immunodeficiency Syndrome 4

Interventions

Temozolomide 62Cyclophosphamide 60Radiotherapy 48Doxorubicin 36Filgrastim 26Radiation 24Irinotecan 24fludarabine 23Gemcitabine 23Magnetic Resonance Spectroscopy 21Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × tecogalan × Sarcoma × Clear all
NCT00002136 2005-06-24

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002137 2005-06-24

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002138 2005-06-24

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002342 2005-06-24

A Study of Tecogalan Sodium

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡